In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Steven Muntner

New York, NY
Steven Muntner is Vice President in charge of deals for Informa Pharma including Strategic Transactions and Medtrack.  In this role, he oversees all of the healthcare deals content spanning partnerships, mergers and acquisitions, and public and private financings for pharmaceutical, biotech, diagnostic and medical device companies.  Prior to this role, Mr. Muntner was an analyst with Medtrack and Strategic Transactions and joined Informa in the beginning of 2013.  Mr. Muntner is a published author, having written content for Nature Biotech and the Wall Street Journal.  Before his tenure at Informa, Mr. Muntner worked across the financial services industry in healthcare investment banking, with several years of experience at Natixis and Ladenburg Thalmann.  He graduated with a bachelors in business administration from Emory University in Atlanta, Georgia.  
Advertisement
Set Alert for Articles By Steven Muntner

Latest From Steven Muntner

Deals Shaping The Medical Industry, April 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.

Deals BioPharmaceutical

Deals Shaping The Medical Industry, March 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.

Deals BioPharmaceutical

Venture Funding Deals

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in January and February 2017.

Commercial StartUps and SMEs

Tech Transfer Roundup: Repeat Business As Boehringer, Vanderbilt Collaborate Further On KRAS

This month's roundup also records a second tie-up between Florida State and Spotlight Innovations, while Taiwan's Lin Biosciences licenses global rights to a CDC7 kinase inhibitor from Columbia and Memorial Sloan Kettering.

Deals StartUps and SMEs

Tech Transfer Roundup: Aduro Hopes Stanford Algorithm Will Optimize Its IO Candidates

Aduro Biotech discusses what it looks for in an academic collaboration. Plus, Sarepta adds gene therapies to its Duchenne pipeline from Nationwide Children's Hospital and Columbia University out-licenses IP to a pair of biotechs.

Deals StartUps and SMEs

Venture Funding Deals: Takeda Ups Its Bet On Immuno-Oncology Play Maverick

Biscayne and Japanese CRO SNBL create spin-outs to advance programs; liver disease specialist Ascletis gains funds as it shifts away from HCV; Neon gets $100m to put into its cancer vaccines; and other highlights of recent VC funding.

StartUps and SMEs Financing
See All
Advertisement
UsernamePublicRestriction

Register